MWG Management Ltd.

In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 14, 2024), MWG Management Ltd. reported 3 stock positions worth $135.1 million. Its top holding was Beam Therapeutics (BEAM) at 57.4% of the portfolio, followed by Lyell Immunopharma (LYEL, 33.3%) and Prime Medicine (PRME, 9.3%). Its holdings were unchanged from Q4 2023.

Most Recent 13F
Q3 2025
Location
Washington, DC
CIK
0001845151
Portfolio Value
$135.1M (Q1 2024)
SEC Filing
0000950123-24-005128 ↗ filed May 14, 2024

Holdings Value

0$50.0M$100.0M$150.0M Q1 2024: $135.1M $135.1M Q1 2024 Q2 2024: $91.6M Q2 2024 Q3 2024: $90.3M Q3 2024 Q4 2024: $74.4M Q4 2024 Q1 2025: $58.7M Q1 2025 Q2 2025: $51.9M Q2 2025 Q3 2025: $81.3M Q3 2025

Holdings 3 stocks · $135.1M
BEAM Beam Therapeutics Inc. 57.42% 2,346,934 $77.5M No change
LYEL Lyell Immunopharma Inc. 33.29% 20,162,332 $45.0M No change
PRME Prime Medicine Inc. 9.29% 1,792,210 $12.5M No change

Portfolio Sells Q4 2023 → Q1 2024
None this quarter.

Portfolio Buys Q4 2023 → Q1 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2025 3$81.3MBEAM, LYEL, PRME
Q2 2025 3$51.9MBEAM, LYEL, PRME
Q1 2025 3$58.7MBEAM, LYEL, PRME
Q4 2024 3$74.4MBEAM, LYEL, PRME
Q3 2024 3$90.3MBEAM, LYEL, PRME
Q2 2024 3$91.6MBEAM, LYEL, PRME
Q1 2024 3$135.1MBEAM, LYEL, PRME